Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders

Background and Objectives Neuromyelitis optica spectrum disorders (NMOSD) is widely recognized as a CNS demyelinating disease associated with AQP4-IgG (T cell–dependent antibody), and its trigger is still unclear. In addition, although the treatment of NMOSD currently can rely on traditional immunosuppressive and modulating agents, effective methods to predict the efficacy of these therapeutics are lacking. Methods In this study, high-throughput T-cell receptor (TCR) sequencing was performed on peripheral blood from 151 pretreatment patients with AQP4-IgG+ NMOSD and 151 healthy individuals. We compared the TCR repertoire of those with NMOSD with that of healthy individuals and identified TCR clones that were significantly enriched in NMOSD. In addition, we treated 28 patients with AQP4-IgG+ NMOSD with immunosuppressants and followed up for 6 months to compare changes in NMOSD-specific TCRs (NMOSD-TCRs) before and after treatment. Moreover, we analyzed transcriptome and single-cell B-cell receptor (BCR) data from public databases and performed T-cell activation experiments using antigenic epitopes of cytomegalovirus (CMV) to further explore the triggers of AQP4-IgG+ NMOSD. Results Compared with healthy controls, patients with AQP4-IgG+ NMOSD had significantly reduced diversity and shorter CDR3 length of TCRβ repertoire. Furthermore, we identified 597 NMOSD-TCRs with a high sequence similarity that have the potential to be used in the diagnosis and prognosis of NMOSD. The characterization of NMOSD-TCRs and pathology-associated clonotype annotation indicated that the occurrence of AQP4-IgG+ NMOSD may be associated with CMV infection, which was further corroborated by transcriptome and single-cell BCR analysis results from public databases and T-cell activation experiments. Discussion Our findings suggest that the occurrence of AQP4-IgG+ NMOSD may be associated with CMV infection. In conclusion, our study provides new clues to uncover the causative factors of AQP4-IgG+ NMOSD and provides a theoretical foundation for treating and monitoring the disease.

[1]  S. Tada,et al.  Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder , 2022, Neurology: Neuroimmunology & Neuroinflammation.

[2]  Xiuqing Zhang,et al.  T Cell Repertoire Abnormality in Immunodeficiency Patients with DNA Repair and Methylation Defects , 2021, Journal of clinical immunology.

[3]  C. Deane,et al.  SAbDab in the age of biotherapeutics: updates including SAbDab-nano, the nanobody structure tracker , 2021, Nucleic Acids Res..

[4]  M. Apiwattanakul,et al.  Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review. , 2021, Multiple sclerosis and related disorders.

[5]  B. Weinshenker,et al.  Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials , 2021, Nature Reviews Neurology.

[6]  D. Carbone,et al.  Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer. , 2021, Lung cancer.

[7]  F. Shi,et al.  B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[8]  O. Kwon,et al.  Serum Peptide Immunoglobulin G Autoantibody Response in Patients with Different Central Nervous System Inflammatory Demyelinating Disorders , 2021, Diagnostics.

[9]  Xinghu Zhang,et al.  Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder , 2021, Frontiers in Immunology.

[10]  J. Criniti,et al.  An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD , 2021, Frontiers in Immunology.

[11]  L. Cowell,et al.  TCRMatch: Predicting T-Cell Receptor Specificity Based on Sequence Similarity to Previously Characterized Receptors , 2020, bioRxiv.

[12]  Z. Shi,et al.  CD8+ T cell subpopulations and pro‐inflammatory cytokines in neuromyelitis optica spectrum disorder , 2020, Annals of clinical and translational neurology.

[13]  F. Paul,et al.  Neuromyelitis optica , 2020, Nature Reviews Disease Primers.

[14]  J. Derisi,et al.  A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis , 2020, Proceedings of the National Academy of Sciences.

[15]  Damon H. May,et al.  Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels , 2020, medRxiv.

[16]  Ying Lin,et al.  Cytomegalovirus Infection in an Adult Patient With Neuromyelitis Optica and Acute Hemorrhagic Rectal Ulcer: Case Report and Literature Review , 2020, Frontiers in Immunology.

[17]  J. Beckford,et al.  Deciphering the TCR Repertoire to Solve the COVID-19 Mystery , 2020, Trends in Pharmacological Sciences.

[18]  F. Paul,et al.  Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica , 2020, Nature Communications.

[19]  Z. Shi,et al.  Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study , 2019, Journal of Neuroimmunology.

[20]  Z. Shi,et al.  Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study , 2019, Journal of Neurology.

[21]  S. Zamvil,et al.  B cells in autoimmune and neurodegenerative central nervous system diseases , 2019, Nature Reviews Neuroscience.

[22]  Gheyath K Nasrallah,et al.  The Current Status of Cytomegalovirus (CMV) Prevalence in the MENA Region: A Systematic Review , 2019, Pathogens.

[23]  S. Broadley,et al.  AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD , 2019, Front. Neurol..

[24]  Fei Gao,et al.  PIRD: Pan immune repertoire database. , 2019, Bioinformatics.

[25]  Claire Marks,et al.  Thera-SAbDab: the Therapeutic Structural Antibody Database , 2019, bioRxiv.

[26]  Mingyan Fang,et al.  T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis , 2019, Annals of the rheumatic diseases.

[27]  D. Zeng,et al.  Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders , 2019, Brain : a journal of neurology.

[28]  Fan Zhang,et al.  Fast, sensitive, and accurate integration of single cell data with Harmony , 2018, bioRxiv.

[29]  Huanming Yang,et al.  PIRD: Pan immune repertoire database , 2018, bioRxiv.

[30]  S. Zheng,et al.  Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: A Chinese pilot study , 2018, Multiple sclerosis.

[31]  Zev J. Gartner,et al.  DoubletFinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors , 2018, bioRxiv.

[32]  Robert E Handsaker,et al.  A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica , 2018, Nature Communications.

[33]  Anna Lorenc,et al.  T cell receptor β-chains display abnormal shortening and repertoire sharing in type 1 diabetes , 2017, Nature Communications.

[34]  B. Giometto,et al.  Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD) , 2017, Neurological Sciences.

[35]  Jaime Prilusky,et al.  McPAS‐TCR: a manually curated catalogue of pathology‐associated T cell receptor sequences , 2017, Bioinform..

[36]  Andrew K. Sewell,et al.  VDJdb: a curated database of T-cell receptor sequences with known antigen specificity , 2017, Nucleic Acids Res..

[37]  K. Dear,et al.  Incidence and prevalence of NMOSD in Australia and New Zealand , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[38]  William S. DeWitt,et al.  Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire , 2017, Nature Genetics.

[39]  Dima Kozakov,et al.  The ClusPro web server for protein–protein docking , 2017, Nature Protocols.

[40]  Alexandre M. J. J. Bonvin,et al.  PRODIGY: a web server for predicting the binding affinity of protein-protein complexes , 2016, Bioinform..

[41]  K. Fujihara,et al.  Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD , 2016, Acta neuropathologica communications.

[42]  S. Baranzini,et al.  Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens , 2016, Annals of neurology.

[43]  Grace X. Y. Zheng,et al.  Massively parallel digital transcriptional profiling of single cells , 2016, Nature Communications.

[44]  Jiye Shi,et al.  ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation , 2016, mAbs.

[45]  J. Sauver,et al.  Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum , 2016, Annals of neurology.

[46]  T. Ben-Hur,et al.  T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO). , 2016, Multiple sclerosis and related disorders.

[47]  K. Fujihara,et al.  Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS , 2015, Acta Neuropathologica.

[48]  Xun Xu,et al.  IMonitor: A Robust Pipeline for TCR and BCR Repertoire Analysis , 2015, Genetics.

[49]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[50]  S. Zamvil,et al.  Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[51]  Jacqueline A Palace,et al.  Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.

[52]  R. Emerson,et al.  Using synthetic templates to design an unbiased multiplex PCR assay , 2013, Nature Communications.

[53]  S. Miller,et al.  Virus infection, antiviral immunity, and autoimmunity , 2013, Immunological reviews.

[54]  Radhika A. Vaishnav,et al.  Aquaporin 4 molecular mimicry and implications for neuromyelitis optica , 2013, Journal of Neuroimmunology.

[55]  V. Bittencourt,et al.  The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients , 2012, Journal of Clinical Immunology.

[56]  B. Weinshenker,et al.  Effects of age and sex on aquaporin-4 autoimmunity. , 2012, Archives of neurology.

[57]  R. Stroud,et al.  Aquaporin 4-Specific T Cells in Neuromyelitis Optica Exhibit a Th17 Bias and Recognize Clostridium ABC Transporter , 2012, Annals of neurology.

[58]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[59]  K. Fujihara,et al.  Pathogenic T cell responses against aquaporin 4 , 2011, Acta Neuropathologica.

[60]  Yuge Wang,et al.  HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese , 2011, Journal of Neuroimmunology.

[61]  T. Kanda,et al.  A serological analysis of viral and bacterial infections associated with neuromyelitis optica , 2011, Journal of the Neurological Sciences.

[62]  M. Cannon,et al.  Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection , 2010, Reviews in medical virology.

[63]  K. Wandinger,et al.  Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen , 2010, Journal of the Neurological Sciences.

[64]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[65]  A. Bar-Or,et al.  Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment1 , 2008, The Journal of Immunology.

[66]  R. Meuli,et al.  Neuromyelitis optica following CMV primo‐infection , 2007, Journal of internal medicine.

[67]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[68]  T. Compton,et al.  Human Cytomegalovirus Elicits a Coordinated Cellular Antiviral Response via Envelope Glycoprotein B , 2004, Journal of Virology.

[69]  V. Bittencourt,et al.  The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients , 2012, Journal of Clinical Immunology.

[70]  V. Lennon,et al.  Clinical utility of testing AQP4-IgG in CSF , 2016, Neurology: Neuroimmunology & Neuroinflammation.